Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial

Source :: GlobeNewswire. March 16, 2023
Publication Year :: 2023
Abstract: Subjects completed 16-week treatment with no significant safety issues Topline results expected in the first half of 2023 SCOTTSDALE, Ariz., March 16, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: [...]

Subjects :: Medical research
Medicine, Experimental
Skin diseases
Dermatology -- Formulae, receipts, prescriptions
Minocycline -- Product development
Clinical trials
Dermatologic agents -- Product development
Banking, finance and accounting industries
Business

Tools